CLERICO, ALDO
 Distribuzione geografica
Continente #
NA - Nord America 33.814
EU - Europa 25.411
AS - Asia 3.410
Continente sconosciuto - Info sul continente non disponibili 202
SA - Sud America 14
OC - Oceania 12
AF - Africa 9
Totale 62.872
Nazione #
US - Stati Uniti d'America 33.128
GB - Regno Unito 14.247
UA - Ucraina 3.869
DE - Germania 2.094
IT - Italia 1.900
CN - Cina 1.525
VN - Vietnam 1.446
SE - Svezia 843
DK - Danimarca 782
CA - Canada 679
FI - Finlandia 618
PL - Polonia 534
FR - Francia 213
SG - Singapore 210
EU - Europa 202
IE - Irlanda 195
HK - Hong Kong 90
KR - Corea 46
IN - India 37
RU - Federazione Russa 29
RO - Romania 27
NL - Olanda 20
SK - Slovacchia (Repubblica Slovacca) 14
IL - Israele 10
IR - Iran 10
AU - Australia 9
TR - Turchia 9
BE - Belgio 6
BR - Brasile 6
JP - Giappone 6
CZ - Repubblica Ceca 5
ID - Indonesia 5
MX - Messico 5
CH - Svizzera 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SM - San Marino 3
TW - Taiwan 3
ZA - Sudafrica 3
AM - Armenia 2
AR - Argentina 2
AT - Austria 2
CL - Cile 2
EC - Ecuador 2
EG - Egitto 2
ES - Italia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
NG - Nigeria 2
RS - Serbia 2
CO - Colombia 1
DZ - Algeria 1
GT - Guatemala 1
HR - Croazia 1
MA - Marocco 1
NI - Nicaragua 1
PH - Filippine 1
SA - Arabia Saudita 1
SR - Suriname 1
TH - Thailandia 1
Totale 62.872
Città #
Southend 12.638
Woodbridge 5.121
Ann Arbor 4.000
Chandler 3.260
Houston 2.984
San Mateo 2.512
Dearborn 1.956
Jacksonville 1.916
Falls Church 1.474
Fairfield 1.187
Beijing 1.075
Seattle 1.018
Cambridge 945
Dong Ket 828
Wilmington 803
Stevenage 761
Portsmouth 692
Boardman 656
Lawrence 610
Warsaw 528
Ashburn 503
Pisa 457
Ottawa 454
Brooklyn 416
Montréal 195
Old Bridge 185
Dublin 182
San Diego 136
Redwood City 101
Singapore 101
Norwalk 95
Milan 55
London 49
Rome 38
Fremont 37
Seoul 32
Central District 30
Augusta 29
Simi Valley 29
Hefei 27
Salerno 27
Washington 24
Bologna 23
Mountain View 23
Nanjing 21
Kansas City 20
Timisoara 20
Kunming 19
Napoli 18
Pavia 18
Hanover 16
Jinan 16
Trieste 15
Bratislava 14
Foggia 13
Guangzhou 13
Hong Kong 12
Islington 12
Wayne 12
Florence 11
Fuzhou 11
Nanchang 11
Chiswick 10
Palermo 10
Shanghai 10
Leawood 9
Livorno 9
Shenzhen 9
Toronto 9
Frankfurt am Main 8
Hebei 8
Helsinki 8
Potenza 8
Sanayi 8
West Jordan 8
Xian 8
Andover 7
Brescia 7
Daejeon 7
Duncan 7
Montepulciano 7
Naples 7
Padova 7
Provo 7
Grammichele 6
Lucca 6
Paris 6
Roccaforzata 6
Ronchi Dei Legionari 6
San Felice D'ocre 6
Verona 6
Wuhan 6
Catania 5
Dongguan 5
Perugia 5
Pietrasanta 5
San Giuliano Terme 5
Viareggio 5
Appignano 4
Bari 4
Totale 48.748
Nome #
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 563
Downregulation of von Willebrand Factor prevents Ang II-induced endothelin-1 expression independently of eNOS activation in porcine endothelial cells 235
siRNA-mediated targeting of endothelial VWF prevents ET-1 upregulation in porcine aortic endothelial cells chronically exposed to angiotensin II 235
Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. 230
The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. 208
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 189
Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system. 187
Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform 183
Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure 171
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 166
Proposta per l’utilizzo in Pronto Soccorso delle troponine cardiache misurate con metodi di ultima generazione in pazienti con sospetto di sindrome coronarica acuta senza sopraslivellamento del tratto ST 164
Marcatori di rimodellamento e fibrosi cardiaca 159
B-type natriuretic peptide secretion following scuba diving 156
State of the art of BNP and NT-proBNP immunoassays: The CardioOrmoCheck study 155
Valutazione delle caratteristiche analitiche di un nuovo metodo di dosaggio del BNP 154
No variation in Hsp70 mRNA level during cardiac surgery in pediatric patients evaluated by semiquantitative RT-PCR 153
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 152
Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance 152
Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. 150
Prognostic value of combined use of B-ype natriuretic peptides and interleukine-6 in predicting cardiac mortalità in end-stage renal disease patients 150
Valutazione esterna di qualità dei peptidi natriuretici BNP e NT-proBNP: risultati del programma Cardioormocheck 149
Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results. 149
Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure 149
Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. 148
Methodological assessment of mitochondrial respiratory chain-enzyme activities in cardiac tissue 148
Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. 147
Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: New challenges and perspectives 145
Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method 144
S-nitrosoglutathione as a substrate of gamma-glutamyltransferase (GGT)- A kinetic study 143
Deoxyribonucleic acid damage in human lymphocytes after percutaneous transluminal coronary angioplasty 142
The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery 141
Distribution of plasma cardiac troponin-I values in healthy subjects: pathophysiological considerations 140
N-terminal proB-type natriuretic peptide (NT-proBNP) is superior to BNP for the detection of eraly/mild forms of heart failure 140
The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex 139
State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC). 139
N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives 139
Stato dell’arte dell’immunodosaggio dei peptidi natriuretici di tipo B 139
Comparison of the diagnostic accuracy of BNP and NT-proBNP in acute and chronic heart failure. Reply Letter 138
125I-Endothelin-1 binding sites in human cardiac tissue 138
Rilevanza clinica e interpretazione dei marcatori biochimici nello scompenso cardiaco 138
Heat shock protein 70-1 gene expression in pediatric heart surgery using blood cardioplegia. 136
New and emerging biomarkers of heart failure 136
Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides 136
Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients with Stable Angina 136
The non-thyroidal illness syndrome after coronary artery bypass grafting: a 6-month follow-up study. 135
New biomarkers for risk stratifications in patients with heart failure: high-sensitivity troponin I and galectin-3 135
Clinical relevance of time course of BNP levels in neonates with congenital heart diseases 135
Natriuretic peptide testing in primary care patients. 134
A sensitive and accurate plasma noradrenaline assay using a modified fluorimetric method. 134
BNP values in the first days of life measured with an automated immunoassay platform 134
Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review 134
Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. 133
Ultrafiltration: a rational treatment for heart failure. 133
Gamma-glumamyl-transferase levels are associated with inflammatory activation, myocardial dysfunction and mortality in pateints with ST-elevation myocardial infarction 133
Reference values for urinary neutrophil gelatinase-associated lipocalin (NGAL) in pediatric age measured with a fully automated chemiluminescent platform 133
Evaluation of analytical performance of a novel immunoenzymometric assay for cTnI. 132
Prognostic complexity of heart failure and network analysis: the holistic risk stratification 131
Genomic medicine and thrombotic risk: who, when, how and why? 131
Plasma gamma-glutamyltransferase fractions: diagnostic and prognostic predictive value 131
Evaluation of analytical performance and comparison of clinical results of the new generation method AccuTnI+3 for the measurement of cardiac troponin I using both patients and quality control plasma samples 131
Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences 131
Evaluation of Analytical Performance of the Siemens ADVIA TnI Ultra Immunoassay 130
Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: compariosn with the old method and the Access system 129
Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. 129
Diagnostic, prognostic and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases 128
Diagnosis of preclinical /mild heart failure with B-type natriuretic peptides: compariosn betwwen BNP and NT-proBNP immunoassay methods 128
Analytical and clinical preformance of NT-proBNP immunoassay 128
Comparison of two BNP immunoassays using the same antibodies and standard materials 128
N-terminal fragment of brain natriuretic peptide predicts vascular health and subclinical atherosclerosis: results from MEHLP study 128
Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation 128
Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects. 127
Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study 127
Methodological and clinical evaluation of the Liaison automated analyser for the qunatitative detrmination of 25-OH-vitamin D. 127
Determinazione dei siti di legame dell’endotelina su membrane di atrio e di ventricolo bovino: un modello per studi di legame du tessuto cardioaco umano 127
Plasma levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and N-terminal fragment of pro-ANP in heart failure and in controls 127
Cheyne-Stokes respiration is associated with neurohormonal activation in patients with heart failure 127
Predictive Value of NT-proBNP in Patients with Acute Myocardial Infarction 127
Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients 126
Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations. 126
Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: Is their assay merely a marker of cardiac disease? 126
ANP tissue extraction is not changed by large icrease of its plasma levels induced by pacing 126
Gamma-glutamyltransferase levels are associated with inflammatory activation, myocardial dysfunction and in-hospital mortality in patients with ST-elevation myocardial infarction 126
Cardiac Natriuretic Hormones, Neuro-Hormones, Thyroid Hormones and Cytokines in Normal Subjects and Patients with Heart Failure. 125
Circadian rhythm of myoglobin serum levels in normal subjects 125
Endocrine paradox in heart failure: resistance to biological effetcs of cardiac natriuretic hormones 124
Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease 124
Measurement of H4-LDH: a comparative evaluation of RIA and enzymatic tests 124
B-type plasma natriuretic hormone level in operated Fallot patients 124
Cardiac biomarker testing in the clinical laboratory:Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. 124
State of the Art of Immunoassay Methods for B-Type Natriuretic Peptides: an Update 123
Cardiac natriuretic hormones as clinical markers: instructions for use. 123
Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide 123
Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. 123
Old and new biomarkers of heart failure 123
When gonads talk to the heart sex hormones and cardiac endocrine function. 123
null 123
Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin i 123
Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review 122
Direct comparison of B-Type Natriuretic Peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data 122
Circulating levels of cardiac natriuretic peptides measured by highly sensitive and specific IRMA methods in normal subjects and in patients with heart failure 122
Totale 14.466
Categoria #
all - tutte 238.511
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 238.511


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.996 336 98 638 443 1.512 1.208 1.704 414 1.128 108 95 1.312
2020/202111.162 332 1.907 734 473 770 1.690 1.093 324 741 382 1.035 1.681
2021/20228.252 276 1.896 208 966 62 55 887 1.779 511 924 56 632
2022/20236.603 616 117 70 1.176 1.151 1.248 12 531 1.101 143 267 171
2023/20241.761 370 85 290 104 72 276 232 72 25 47 29 159
2024/202587 87 0 0 0 0 0 0 0 0 0 0 0
Totale 63.086